Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Highlighted with 37 tables and 57 figures, this 121-page report “Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
• Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
• Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others
Based on Indication, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Cancer
• Autoimmune Disease
• Blood Disorder
• Diabetes
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications
Based on Manufacturing, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Contract Manufacturing
• Inhouse Manufacturing
Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Hospitals and Clinics
• Research Institutes
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Europe Market by Product Type 43
3.1 Market Overview by Product Type 43
3.2 Recombinant Non-glycosylated Biosimilars 45
3.2.1 Insulin 47
3.2.2 Recombinant Human Growth Hormone (rHGH) 48
3.2.3 Granulocyte Colony Stimulating Factor 49
3.2.4 Interferon 50
3.3 Recombinant Glycosylated Biosimilars 51
3.3.1 Monoclonal Antibodies (mAb) 52
3.3.2 Erythropoietin (EPO) 53
3.3.3 Follicle Stimulating Hormone 54
3.4 Recombinant Peptides and Others 55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56
3.4.2 Parathyroid Hormone 57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58
4 Segmentation of Europe Market by Indication 59
4.1 Market Overview by Indication 59
4.2 Cancer 61
4.3 Autoimmune Disease 62
4.4 Blood Disorder 63
4.5 Diabetes 64
4.6 Growth Hormone Deficiency 65
4.7 Infectious Diseases 66
4.8 Other Indications 67
5 Segmentation of Europe Market by Manufacturing 68
5.1 Market Overview by Manufacturing 68
5.2 Contract Manufacturing 70
5.3 Inhouse Manufacturing 71
6 Segmentation of Europe Market by End User 72
6.1 Market Overview by End User 72
6.2 Hospitals and Clinics 74
6.3 Research Institutes 75
6.4 Other End Users 76
7 European Market 2019-2030 by Country 77
7.1 Overview of European Market 77
7.2 Germany 82
7.3 U.K. 85
7.4 France 88
7.5 Spain 90
7.6 Italy 92
7.7 Russia 94
7.8 Rest of European Market 96
8 Competitive Landscape 98
8.1 Overview of Key Vendors 98
8.2 New Product Launch, Partnership, Investment, and M&A 102
8.3 Company Profiles 103
AMEGA Biotech S.A. 103
Apotex Inc. 105
Biocon Ltd 106
Biogen Inc. 107
Boehringer Ingelheim 108
Celltrion, Inc. 109
Dr. Reddy’s Laboratories Ltd. 110
Eli Lilly and Company 111
Intas Pharmaceuticals Ltd. 112
LG Chem, Ltd. 113
Merck and Co. Inc. 114
Mylan N.V. 115
Pfizer Inc. 116
Samsung Biologics Co., Ltd. 117
Sandoz International GmbH 118
STADA Arzneimittel AG 119
Teva Pharmaceutical Industries Ltd. 120
RELATED REPORTS 121
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
